In short
This article discusses ongoing clinical trials investigating the use of a novel gene therapy called HORA-PDE6B for treating retinitis pigmentosa (RP) caused by mutations in the PDE6B gene. HORA-PDE6B is an adenovirus-associated viral vector that carries the human PDE6B gene, designed to be administered through a subretinal injection. The trials aim to assess the safety and potential efficacy of this treatment in patients with PDE6B-related retinitis pigmentosa, a rare inherited eye disorder that causes progressive vision loss.
At a glance
- Treatment Name
- HORA-PDE6B (Adenovirus Associated Viral Vector Serotype 5 Containing The Human PDE6B Gene)
- Condition Treated
- Retinitis Pigmentosa caused by PDE6B gene mutations
- Administration Method
- Unilateral subretinal injection
- Trial Phase
- Phase 1/2
- Primary Objective
- Assess safety of HORA-PDE6B administration
- Secondary Objectives
- Evaluate immune responses, viral shedding, and treatment efficacy
- Key Eligibility Criteria
- Confirmed PDE6B mutations, specific visual acuity and field preservation, age ≥18 (or ≥13 for one cohort)
- Main Assessments
- Visual acuity, color vision, visual fields, ERG, OCT, quality of life
What is HORA-PDE6B?
HORA-PDE6B is an experimental gene therapy treatment being developed for patients with a specific type of retinitis pigmentosa. Its full name is "Adenovirus Associated Viral Vector Serotype 5 Containing the Human PDE6B Gene," but it's also known by the shorter name HORA-PDE6B. This therapy is designed to treat retinitis pigmentosa caused by mutations in the PDE6B gene.
Target Condition: Retinitis Pigmentosa
Retinitis pigmentosa is a group of rare genetic disorders that involve a breakdown and loss of cells in the retina, which is the light-sensitive tissue at the back of the eye. In the case of PDE6B-related retinitis pigmentosa, the condition is specifically caused by mutations in the PDE6B gene. This gene is responsible for producing an important enzyme in the visual cycle, and when it's not working correctly, it can lead to vision loss.
How HORA-PDE6B Works
HORA-PDE6B is a type of gene therapy. It uses a modified virus (adenovirus associated viral vector serotype 5) to deliver a healthy copy of the PDE6B gene to the retina. The goal is to provide the cells in the retina with the correct instructions to produce the missing or faulty enzyme, potentially slowing or stopping the progression of vision loss.
Clinical Trial Details
A clinical trial is currently underway to test the safety and potential effectiveness of HORA-PDE6B. This is a Phase 1/2 trial, which means it's an early-stage study primarily focused on safety, but also looking at potential signs of effectiveness. The treatment is administered through a subretinal injection, which means it's injected directly under the retina of one eye.
Eligibility Criteria
The trial has specific criteria for who can participate. Some key points include:
- Patients must have retinitis pigmentosa caused by mutations in the PDE6B gene
- Participants must be at least 13 years old (for some parts of the study, the minimum age is 18)
- Patients must still have some remaining central retinal function
- Certain levels of visual acuity and visual field are required, depending on which part of the study a patient might join
There are also many factors that might exclude someone from participating, such as certain other medical conditions or previous treatments.
Safety and Efficacy Assessment
The main goal of this trial is to assess the safety of HORA-PDE6B. Researchers will be closely monitoring participants for any side effects or complications. They'll be looking at things like:
- Changes in eye health through routine eye exams
- Signs of inflammation in the eye
- How well the retina and surrounding tissues tolerate the treatment
- Overall health indicators like vital signs and laboratory tests
In addition to safety, the researchers will also be looking for signs that the treatment might be working. They'll be conducting various tests to measure visual function, including:
- Visual acuity tests (how well you can see at different distances)
- Color vision tests
- Visual field tests (how wide an area you can see)
- Various types of retinal function tests (ERG, microperimetry)
- Tests of how well participants can move around in different lighting conditions
They'll also be using imaging techniques to look at the structure of the retina and tracking changes in quality of life for adult participants.
Potential Benefits and Risks
As an experimental treatment, it's important to understand that the benefits of HORA-PDE6B are not yet proven. The hope is that it could slow or stop the progression of vision loss in people with PDE6B-related retinitis pigmentosa, but this needs to be demonstrated through careful study.
There are also potential risks to consider. Gene therapy and eye injections can have side effects, which could include inflammation, changes in eye pressure, or other complications. The full range of possible side effects may not yet be known, which is why careful monitoring during the trial is so important.
If you have retinitis pigmentosa related to PDE6B mutations and are interested in this trial, it's important to discuss it thoroughly with your doctor. They can help you understand if you might be eligible and whether the potential benefits outweigh the risks in your individual case.